TRIM47-facilitated PLK1 stabilization promotes the proliferation of liver cancer cells
Year: 2025
Type: article
Language: en
Topic: interferon and immune responses
Authors and affiliations:
raw_author_name: Tao Xie
raw_affiliation_strings: School of Basic Medical Sciences, Institute of Biomedical Innovation, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Xiaoqi Fan
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Tian Yu
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Qing Zhu
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Qi Zhang
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Na Li
raw_affiliation_strings: School of Future Technology, Nanchang University, Nanchang, China
The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Tao Wang
raw_affiliation_strings: HuanKui Academy, Jiangxi Medical College, Nanchang University, Nanchang, China
The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Yisong Qian
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Keyu Deng
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Hongbo Xin
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China
raw_author_name: Yong Li
raw_affiliation_strings: Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. liyong@ncu.edu.cn
raw_author_name: Xuan Huang
raw_affiliation_strings: The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China. huangxuan@ncu.edu.cn